Data sets up phase 3 trials for Novo's amycretin in diabetes

Novartis cuts hundreds of jobs; Novo’s dual-acting diabetes drug heading to Phase 3

The layoffs affect Swiss manufacturing facilities. Elsewhere, the FDA pushed back an approval deadline and a mid-stage study showed Novo’s amycretin helps regulate blood sugar.

Data sets up phase 3 trials for Novo's amycretin in diabetes

Data sets up phase 3 trials for Novo's amycretin in diabetes Phil.Taylor Tue, 25/11/2025 - 14:02 Bookmark this

Novo Nordisk moves next-gen drug amycretin to late-stage diabetes trial after promising data

Novo Nordisk reported promising mid-stage results for its experimental drug amycretin in diabetes patients on Tuesday.

Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes

GlobalData analyst Shehroz Mahmood notes that Novo Nordisk's amycretin could become the "next frontier" in obesity and T2D.The post Novo Nordisk to advance amylin agonist to Phase III in type 2 diabetes appeared first on Clinical Trials Arena.

Novo Nordisk Advances Amycretin to Late-Stage Trials for Diabetes Treatment

Novo Nordisk has advanced its next-generation diabetes […] The post Novo Nordisk Advances Amycretin to Late-Stage Trials for Diabetes Treatment first appeared on GeneOnline News. The post Novo Nordisk Advances Amycretin to Late-Stage Trials for Diabetes Treatment appeared first on GeneOnline News.